Imprimis Pharmaceuticals Stock News

Harrow (HROW) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a tren

Even though the company failed to fit the analysts' expectations for EPS, the company's financial indicators are growing. The company's gross margin is growing, operating expenses are decreasing, and

Virtu Financial LLC purchased a new stake in Harrow Health, Inc. (NASDAQ:HROW) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 14,928 shares of the companys stock, valued at approximately $139,000. Virtu Financial LLC owned approximately 0.06% of Harrow Health as of its []

Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Teladoc Health (TDOC) expects revenues to rise to more than $4 billion in 2024.

Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Harrow Health, Inc. (NASDAQ:HROW) Stock analysts at B. Riley raised their FY2021 earnings per share estimates for Harrow Health in a research report issued to clients and investors on Thursday, November 11th. B. Riley analyst J. Walsh now anticipates that the company will post earnings per share of $0.32 for the year, up from []

Harrow Health's (HROW) CEO Mark L. Baum on Q3 2021 Results - Earnings Call Transcript

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the third qu

The company can grow efficiently; as revenue grows, the Cost of Revenue and SG&A expenses as a % of revenue decrease. Management expects this trend to continue. According to The National Eye Institute

For an undisclosed amount, Harrow Health Inc (NASDAQ: HROW) has agreed to acquire MAQ-100 U.S. and Canadian commercial rights from Wakamoto Pharmaceutical Co Ltd. MAQ-100 is a preservative-free

NASHVILLE, Tenn. & TOKYO--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll,

Harrow Health, Inc. (HROW) CEO Mark Baum on Q2 2021 Results - Earnings Call Transcript